查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1856208

細胞和基因治療市場按治療類型、給藥方式、治療領域、應用和最終用戶分類－2025-2032年全球預測

Cell & Gene Therapy Market by Therapy Type, Delivery Method, Therapeutic Areas, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，細胞和基因治療市場將成長至 713.8 億美元，複合年成長率為 19.95%。

關鍵市場統計數據
基準年 2024 166.5億美元
預計年份：2025年 194.7億美元
預測年份 2032 713.8億美元
複合年成長率 (%) 19.95%

本文提供了一個簡潔的策略框架，闡述了科學進步、製造過程的複雜性以及政策動態如何重塑細胞和基因治療生態系統。

細胞和基因治療生態系統正處於曲折點，科學突破與營運和商業上的複雜性交匯融合。載體工程、精準基因編輯和過繼細胞技術的進步已將過去的理論介入措施轉化為臨床現實。同時，相關人員努力應對生產瓶頸、專業的低溫運輸物流以及不斷變化的監管要求，這需要產業界、學術界和服務供應商之間協調一致的應對措施。

本執行摘要摘要了這些轉變對必須平衡創新與規模的領導者的策略意義。它綜合分析了新興技術發展軌跡、供應鏈脆弱性、支付者和醫療系統動態，以及影響跨境活動的政策環境。其目的是為決策者提供清晰的敘述和實用的視角，以評估近期營運重點和中期策略選擇。透過將技術進步與商業性和監管現實聯繫起來，它重點介紹了可能帶來差異化價值的投資和夥伴關係。

本摘要著重於可操作的見解，而不是抽象的趨勢，使您能夠將您的研發藍圖、製造投資和市場加速策略與當前情況中最關鍵的成功因素保持一致。

科技、管理、監管和商業性力量如何融合，為細胞和基因治療相關人員創造新的策略要務？

細胞和基因治療領域正經歷多維度的變革，這些變革相互交織，重新定義了競爭優勢。技術進步提高了治療的特異性和持久性，而基因編輯平台和載體設計的創新則減少了脫靶效應，並拓寬了治療範圍。同時，生產製造也從客製化、小批量生產轉向更標準化、模組化的方法，優先考慮穩健性、可重複性和成本控制。這種營運模式的演變，使得新一代的受託製造和平台提供者能夠提供可擴展的解決方案。

法律規範正在不斷調整以適應快速發展的科學，日益重視真實世界證據、適應性試驗設計和生命週期監測模型。支付方的參與也在日趨成熟，基於結果的合約和分期付款結構正逐漸成為連結高昂前期成本和長期臨床價值的有效機制。地緣政治和貿易動態促使申辦方重新評估其供應鏈策略，對區域製造和供應商多元化的興趣日益濃厚。因此，夥伴關係和網路編配正成為關鍵的策略槓桿。能夠在分散式價值鏈中整合發現、開發和交付環節，同時保持對核心智慧財產權控制的公司，將更有可能獲得競爭優勢。

綜上所述，這些變化將有利於那些能夠將卓越的科學技術與嚴謹的管理、敏銳的監管意識和商業性創造力相結合的組織，從而將治療方法從有前景的科學轉化為永續的患者可及性。

評估近期關稅政策變化對先進治療藥物供應鏈、本地化生產和風險管理策略的多方面影響

美國2025年關稅政策的改變將為細胞和基因治療產業帶來新的挑戰。試劑、特殊原料和某些生技藥品成分的關稅可能會迫使採購團隊重新評估供應商關係和庫存策略。對於依賴少數關鍵供應商的公司而言，關稅將獎勵它們尋找合格的替代供應商或將部分供應鏈本地化，以降低成本波動和海關延誤帶來的影響。

除了直接成本影響外，關稅政策還會影響與生產地點相關的資本配置決策。企業越來越傾向於權衡建設區域生產能力和維持集中式生產設施（以便獲得規模經濟效益）之間的利弊。關稅可能會使國內或近岸生產更具經濟吸引力，從而加速區域化進程，但也可能擾亂供應鏈，並增加對冗餘檢驗流程的需求。物流也同樣受到影響。清關時間和額外的單據要求可能會對溫度敏感產品的低溫運輸完整性造成壓力，促使企業加大對緊急運輸方案和運輸途中品質監控的投資。

從策略角度來看，關稅環境可能會促使企業深化與上游工程供應商的合作，推行結合合約保護和雙重採購的綜合籌資策略，並加強情境規劃以模擬政策變化。對於監管機構和行業協會而言，這意味著需要加強對話力度，以確保貿易措施不會因造成過重的行政負擔而無意中阻礙患者獲得治療或促進創新。總之，關稅不僅影響細胞和基因治療計畫的成本結構，也影響其全球製造和風險管理架構。

主導細分市場的綜合分析揭示了治療方式、給藥途徑、治療適應症、最終用途和最終用戶畫像如何影響商業性和營運選擇。

深入的細分能清楚展現臨床前景與實際營運的交會點，幫助領導者精準地分配資源。細胞療法分為幹細胞療法和T細胞療法；幹細胞療法可細分為造血幹細胞療法和間質幹細胞療法；T細胞療法分為CAR-T細胞療法和T細胞受體療法；基因療法則分為體外基因療法和體內基因療法，二者各自獨特的載體、遞送方式和安全性特徵都會影響研發進度以及與監管機構的溝通。

給藥途徑細分突顯了臨床實施和病患管理的差異，肌肉注射和靜脈注射需要不同的給藥訓練、輸注能力和監測。治療領域細分揭示了疾病生物學如何決定治療方法的選擇和銷售管道。心血管應用著重於心臟衰竭鬱血性和缺血性心臟疾病；代謝性疾病研究著重於糖尿病和肥胖症；神經病學計畫著重於阿茲海默症、亨廷頓舞蹈症、多發性硬化症、帕金森氏症和脊髓損傷等疾病；腫瘤學研究著重於骨髓惡性腫瘤、淋巴瘤和固態腫瘤。基於應用的細分將臨床應用與研發活動區分開來，前者進一步分為疾病預防和疾病治療，反映了監管終點和支付方期望的差異。最後，最終用戶細分認知到學術和研究機構與醫院和診所之間不同的採購和採用動態，這些機構又進一步細分為推動研究者主導的研究和轉化流程的私人實驗室和大學。

了解這些重疊的細分市場，可以將技術能力與每個細分市場相關的特定監管、臨床和支付方路徑結合，從而更有針對性地進行臨床試驗設計、生產佈局規劃和商業化策略。

區域策略動態和基礎設施的考量將決定臨床開發、生產能力和市場推廣舉措的選址。

區域動態對細胞和基因治療領域的研發策略、監管環境和供應鏈設計有著深遠的影響。在美洲，創新叢集匯聚了臨床專業知識、先進的製造能力和創業投資資金生態系統，以支援快速轉化應用，但相關人員必須應對複雜的支付方格局和各州政策的差異。該地區的法規環境高度重視嚴謹的臨床證據，並輔以早期准入途徑以促進有條件核准。在營運方面，毗鄰主要學術中心有利於建立夥伴關係關係，從而加速早期臨床試驗。

歐洲、中東和非洲地區（EMEA）的監管模式和報銷體係錯綜複雜。歐洲部分地區提供協作評估框架和衛生技術評估途徑，以獎勵長期價值，而其他地區則要求大量的本地證據收集工作。隨著產能投資和專業服務供應商的湧現，該地區的製造業格局正在不斷發展，但企業在該地區開展業務時必須協調不同的跨境監管環境和多樣化的醫療保健資金籌措機制。在基礎設施仍然低度開發的地區，能力建設措施和官民合作關係對於擴大醫療服務覆蓋至關重要。

亞太地區擁有快速成熟的臨床試驗能力，並制定了雄心勃勃的國家策略，試圖成為生物技術製造和商業化中心。該地區各國政府都在投資生物技術基礎設施、放寬先進療法的管制，並進行人才培養計畫。雖然申辦方能夠接觸到龐大的患者群體並降低研發成本，但他們也必須應對監管預期、區域生產要求和市場准入標準方面的差異。

針對這些區域差異制定策略至關重要，以便使試驗設計、生產安排和商業性准入計劃與當地監管現實和支付方期望保持一致。

企業策略如何透過聚焦整合、平台專業化和服務卓越來重塑細胞和基因治療價值鏈的競爭格局？

在先進療法領域，各公司層面的策略正圍繞著一系列核心能力趨於一致，這些核心能力將決定哪些公司能夠勝出，哪些公司將落敗。領先企業正投資於垂直整合的能力，涵蓋藥物發現、載體和細胞工程、製程開發以及商業化規模生產，同時保持靈活的夥伴關係，以實現產能的快速擴張。其他企業則專注於平台技術，例如模組化生產系統、高效價載體生產或封閉式細胞處理系統，並透過授權或合約服務的方式運作這些技術，從而實現規模化和可重複性帶來的價值。

服務供應商和契約製造製造商正發揮日益重要的策略作用，他們提供端到端的解決方案，加快申辦方啟動臨床試驗的速度並降低技術風險。在品質系統、法規遵循和供應編配方面表現卓越的公司，透過確保生產效率和最大限度地減少產品交付延遲，確保與申辦方建立長期合作關係。同時，研發方正透過臨床項目設計、基於生物標記的患者篩選以及與支付方的溝通策略來脫穎而出，將臨床獲益轉化為可信的衛生經濟學論證。

投資者和公司發展活動主要集中在解決行業最緊迫的瓶頸問題：可擴展的載體生產、自動化細胞處理、可靠的滴度和可比性分析、數位化批次記錄系統等。對於這類公司而言，成功與否取決於能否證明其生產過程可重複、臨床結果可靠，以及商業化計劃能夠考慮到報銷的複雜性和國際市場准入壁壘。

領導者可採取切實可行的策略重點，以增強供應鏈韌性、擴大生產規模、協調監管策略並加快支付方採納。

產業領導者應優先採取一系列切實可行的措施，將卓越的科學研究成果轉化為持續的商業性成功。首先，加強供應商夥伴關係並對關鍵投入品進行雙重採購，可以降低地緣政治和關稅波動帶來的風險，同時確保臨床供應的連續性。此外，投資模組化生產能力和自動化技術可以降低批次差異，提高單位成本，從而為內部生產和契約製造夥伴關係創造更多選擇。同時，制定清晰的監管溝通計劃，納入真實世界證據策略和核准後數據收集，可以加快與支付方的對話，並支持基於結果的合約模式。

在營運層面，各組織應加快品質系統和批次分析的數位化，以實現更具預測性的生產控制和更快的監管申報。研發、生產和商業團隊之間的跨職能協作至關重要。將臨床里程碑與生產準備和市場准入要求相銜接的一體化計劃管治，能夠減少後期開發階段的延誤。與醫療服務提供者合作設計可行的給藥途徑，可確保患者獲得治療並簡化應用流程，尤其對於需要專業輸液中心的複雜細胞療法更是如此。

最後，基於情境的策略規劃，透過模擬關稅、監管變化和產能限制等因素的影響，可以幫助領導團隊確定投資和夥伴關係選擇的優先順序。透過結合供應鏈韌性、生產擴充性、監管前瞻性和以支付方為中心的證據生成，行業領導者可以降低其發展路徑的風險，並建立永續的患者獲取途徑。

採用嚴謹的混合方法研究途徑，結合主要相關人員訪談、監管和專利分析以及流程圖檢驗，以驗證營運和策略洞察。

本分析整合了多方面的證據，建構了一個穩健且可重複的細胞和基因治療領域當前動態圖景。主要研究包括對相關人員進行結構化訪談，這些利害關係人包括研發機構、臨床開發團隊、生產和供應鏈負責人、監管事務專業人員以及支付方。次要研究則利用同行評審文獻、已發布的監管指南、臨床試驗註冊資訊、公司披露資訊、專利申請以及物流和低溫運輸研究，檢驗了營運和科學趨勢。

分析技術包括：繪製製造工作流程圖以識別通用瓶頸；進行比較監管分析以揭示不同司法管轄區的差異；以及對專家訪談進行定性編碼以突出反復出現的戰略主題。情境分析用於評估關稅變化和供應鏈中斷對營運的影響。必要時，透過與相關領域專家最後覆核檢驗研究結果，以減少偏差並確保技術準確性。限制包括：該行業的技術創新速度較快，這可能導致能力和法規的快速變化；以及獨特的製造流程差異，這限制了所有研發公司之間的直接可比較性。

儘管存在這些局限性，調查方法強調三角測量和同行檢驗，以產生可用於策略決策、投資評估和營運規劃的可操作見解。

將科學進步與商業性準備及途徑有效整合，進而實現患者持續用藥及業務永續性。

細胞和基因治療領域正進入一個新階段，策略執行而非單純的科學新穎性將決定哪些治療方法可以取得持續的臨床和商業性成功。儘管科學進步不斷拓展可治療疾病的範圍並提高干預的精準度，但通往患者的道路仍需關注生產規模化、供應鏈穩健性、監管合規以及支付方證據的獲取。那些積極建立穩健的供應商網路、採用模組化生產和數位化品質體系，並以可信的真實世界證據與支付方溝通的領導者，將更有能力將臨床成功轉化為廣泛的患者可及性。

全球策略必須靈活，並根據各地區情況進行調整，因為區域監管方式、關稅趨勢和商業模式相互影響。將平台投資與明智的夥伴關係關係結合，並運用情境規劃應對地緣政治和政策變化的組織可以降低執行風險。尤其重要的是，在整個組織內整合科學、營運和商業性計劃可以加速從示範到部署的過渡，確保治療方法惠及有需要的患者，同時維持永續的經營模式。

綜上所述，這些優先事項為在競爭激烈且快速變化的環境中將創新轉化為實際影響提供了切實可行的藍圖。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 利用通用捐贈者平台擴大針對固體癌的同種異體CAR-T細胞療法的規模
  • 將基於 CRISPR 的基因編輯技術應用於罕見遺傳疾病的體內治療，以提高安全性和療效。
  • 採用自動化封閉式系統製造，以降低成本並擴大個人化細胞療法的生產規模。
  • 開發新一代AAV載體平台，以增強基因治療中的組織特異性並降低免疫抗原性
  • 實施分散式照護現場生產模式，用於自體細胞療法的現場生產
  • 能夠克服免疫抑制性腫瘤微環境的多特異性CAR T細胞構建體的出現
  • 生技公司與CDMO建立策略夥伴關係關係，加速細胞療法的臨床開發與商業化
  • 監管協調工作旨在簡化全球核准途徑，加快患者獲得基因療法的速度。
  • 應用人工智慧數位雙胞胎對細胞治療生產流程進行分析和最佳化
  • 對供應鏈創新（包括冷凍保存和低溫運輸物流）的投資，確保了細胞產品在全球的可行性。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 按治療類型分類的細胞和基因治療市場

  • 細胞療法
    • 幹細胞療法
      • 造血幹細胞療法
      • 間質幹細胞療法
    • T細胞療法
      • CAR-T細胞療法
      • 基於T細胞受體（TCR）
  • 基因治療
    • 體外基因治療
    • 體內基因治療

9. 按給藥方式分類的細胞和基因治療市場

  • 肌肉內注射
  • 靜脈

第10章 按治療領域分類的細胞和基因治療市場

  • 心血管系統
    • 鬱血性心臟衰竭
    • 缺血性心臟疾病
  • 代謝紊亂
    • 糖尿病
    • 肥胖
  • 神經系統疾病
    • 阿茲海默症
    • 亨丁頓舞蹈症
    • 多發性硬化症
    • 帕金森氏症
    • 脊髓損傷
  • 腫瘤學
    • 骨髓惡性腫瘤
    • 淋巴瘤
    • 固態腫瘤
  • 眼科

第11章 按應用分類的細胞和基因治療市場

  • 臨床應用
    • 疾病預防
    • 疾病治療
  • 研究與開發

第12章 依最終用戶分類的細胞和基因治療市場

  • 學術和研究機構
    • 私人研究機構
    • 大學
  • 醫院和診所

第13章 細胞與基因治療市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 細胞與基因治療市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國細胞與基因治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • AbbVie Inc.
    • Abeona Therapeutics Inc.
    • Adaptimmune Therapeutics PLC
    • AGC Inc.
    • Alnylam Pharmaceuticals, Inc.
    • American Gene Technologies Inc.
    • Amgen Inc.
    • AnGes, Inc
    • Astellas Pharma Inc.
    • Becton, Dickinson and Company
    • Biogen Inc.
    • Bluebird Bio, Inc.
    • BridgeBio Pharma, Inc.
    • Bristol-Myers Squibb Company
    • CH Boehringer Sohn AG & Co. KG
    • Cellectis SA
    • CRISPR Therapeutics AG
    • F. Hoffmann-La Roche AG
    • Gilead Sciences, Inc.
    • Intellia Therapeutics, Inc.
    • Ionis Pharmaceuticals, Inc.
    • Johnson & Johnson Services Inc.
    • Kyowa Kirin Co., Ltd.
    • Merck KGaA
    • Moderna, Inc.
    • Mustang Bio, Inc.
    • Novartis AG
    • Novo Nordisk A/S
    • Pfizer, Inc.
    • REGENXBIO Inc.
    • Sangamo Therapeutics, Inc.
    • Sarepta Therapeutics, Inc.
    • Shoreline Biosciences
    • Sibiono GeneTech Co. Ltd.
    • Syncona Limited
    • Thermo Fisher Scientific Inc.
    • Vertex Pharmaceuticals Incorporated
Product Code: MRR-450A0628CE5A

The Cell & Gene Therapy Market is projected to grow by USD 71.38 billion at a CAGR of 19.95% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 16.65 billion
Estimated Year [2025] USD 19.47 billion
Forecast Year [2032] USD 71.38 billion
CAGR (%) 19.95%

A concise strategic framing of how scientific advances, manufacturing complexity, and policy dynamics are reshaping the cell and gene therapy ecosystem

The cell and gene therapy ecosystem stands at an inflection point where scientific breakthroughs are converging with operational and commercial complexity. Advances in vector engineering, gene editing precision, and adoptive cell technologies have moved previously theoretical interventions into clinical reality. At the same time, stakeholders are grappling with manufacturing bottlenecks, specialized cold-chain logistics, and evolving regulatory expectations that require coordinated responses across industry, academia, and service providers.

This executive summary distills the strategic implications of these shifts for leaders who must balance innovation with scale. It synthesizes emerging technology trajectories, supply chain vulnerabilities, payer and health system dynamics, and the policy environment shaping cross-border activity. The intent is to equip decision-makers with a clear narrative and practical lenses to evaluate near-term operational priorities and medium-term strategic options. By linking technical advances to commercial and regulatory realities, the analysis clarifies where investments and partnerships are most likely to deliver differentiated value.

Throughout this summary, emphasis is placed on executable insights rather than abstract trends, enabling teams to align R&D roadmaps, manufacturing investments, and go-to-market strategies with the most consequential drivers of success in the current landscape.

How converging technological, operational, regulatory, and commercial forces are creating new strategic imperatives for cell and gene therapy stakeholders

The landscape for cell and gene therapies is transforming along multiple, interlocking dimensions that together redefine competitive advantage. Technological advances are improving specificity and durability of treatments, with innovations in gene-editing platforms and vector design reducing off-target effects and broadening therapeutic applicability. Concurrently, manufacturing is transitioning from bespoke, small-batch processes to more standardized modular approaches that prioritize robustness, reproducibility, and cost control. This operational evolution is enabling a new class of contract manufacturing organizations and platform providers to offer scalable solutions.

Regulatory frameworks are adapting to accommodate rapid scientific progress, increasingly emphasizing real-world evidence, adaptive trial designs, and lifecycle oversight models. Payer engagement is also maturing, with outcome-based contracting and installment payment structures emerging as viable mechanisms to bridge high upfront costs and long-term clinical value. Geopolitical and trade dynamics are prompting sponsors to reassess supply chain strategies, driving interest in regional manufacturing and supplier diversification. As a result, partnerships and network orchestration are becoming central strategic levers: companies that can integrate discovery, development, and delivery across a distributed value chain while retaining control of core intellectual property will gain advantage.

Taken together, these shifts favor organizations that can couple scientific excellence with operational discipline, regulatory acuity, and commercial creativity, enabling therapies to move from promising science to sustainable patient access.

Assessing the multifaceted effects of recent tariff policy changes on supply chains, manufacturing localization, and risk management strategies in advanced therapies

The implementation of tariff changes in the United States in 2025 introduces a new layer of complexity for the cell and gene therapy sector, particularly because the industry relies on globally sourced inputs and cross-border manufacturing chains. Tariffs on reagents, specialized raw materials, and certain biologics components can drive procurement teams to re-evaluate supplier relationships and inventory strategies. For organizations dependent on a narrow set of critical suppliers, tariffs increase the incentive to qualify alternate suppliers or to localize portions of the supply chain to mitigate cost volatility and customs-related delays.

Beyond direct cost impacts, tariff policy influences capital allocation decisions related to manufacturing geography. Firms are increasingly weighing the trade-offs between building regional production capacity and maintaining centralized facilities that benefit from scale. Tariffs can accelerate regionalization by making domestic or nearshore production economically more attractive, but they can also fragment supply networks and amplify the need for redundant validation streams. Logistics flows are likewise affected: customs processing times and additional documentation requirements can stress cold-chain integrity for temperature-sensitive products, prompting greater investment in contingency transport options and quality monitoring across transit.

Strategically, the tariff environment will push companies to deepen upstream engagement with suppliers, to pursue integrated sourcing strategies that combine contractual protections with dual sourcing, and to enhance scenario planning that models policy shifts. For regulators and industry associations, the implications include a greater call for dialogue to ensure that trade measures do not inadvertently impede patient access or innovation by introducing excessive administrative burden. In sum, tariffs shape not only cost structures but also the architecture of global manufacturing and risk management for cell and gene therapy programs.

A segmentation-driven synthesis revealing how therapy modality, delivery route, therapeutic indication, application use case, and end-user profile shape commercial and operational choices

Insightful segmentation clarifies where clinical promise intersects with operational realities and allows leaders to prioritize resources with precision. When the market is parsed by therapy modality, distinct development and manufacturing pathways emerge: cell therapies divide into stem cell approaches and T cell-based approaches, with stem cell therapies further delineated into hematopoietic stem cell therapies and mesenchymal stem cell therapies, while T cell strategies separate into CAR T cell therapy and T cell receptor-based approaches. Gene therapies introduce another axis of differentiation, distinguishing ex vivo gene therapy from in vivo gene therapy, each carrying unique vector, delivery, and safety profiles that influence development timelines and regulatory interactions.

Delivery method segmentation underscores differences in clinical implementation and patient management, with intramuscular and intravenous approaches presenting divergent requirements for administration training, infusion capacity, and monitoring. Therapeutic area segmentation highlights how disease biology drives modality choice and commercial pathways: cardiovascular applications focus on congestive heart failure and ischemic heart disease, metabolic disorder efforts emphasize diabetes and obesity, neurological programs concentrate on conditions such as Alzheimer's disease, Huntington's disease, multiple sclerosis, Parkinson's disease, and spinal cord injuries, and oncology initiatives pivot across hematological malignancies, lymphomas, and solid tumors. Application-based segmentation separates clinical applications from research and development activities, with the former further parsed into disease prevention and disease treatment, reflecting differing regulatory endpoints and payer expectations. Finally, end-user segmentation recognizes divergent purchasing and adoption dynamics between academic and research institutes and hospitals and clinics, with academic and research institutes further distinguished into private research labs and universities that shape investigator-initiated studies and translational pipelines.

Understanding these overlapping segments enables more targeted clinical trial design, manufacturing footprint planning, and commercialization strategies by aligning technical capabilities with the specific regulatory, clinical, and payer pathways associated with each segment.

Regional strategic dynamics and infrastructure considerations that determine where to locate clinical development, manufacturing capacity, and market access initiatives

Regional dynamics exert a powerful influence on development strategies, regulatory approaches, and supply chain design across the cell and gene therapy landscape. In the Americas, innovation clusters concentrate clinical expertise, advanced manufacturing capabilities, and venture funding ecosystems that support rapid translational activity, but stakeholders must manage complex payer landscapes and heterogeneous state-level policies. The regulatory environment in the region reflects an emphasis on rigorous clinical evidence combined with early access pathways that can facilitate conditional approvals; operationally, proximity to major academic centers supports partnerships that accelerate early-phase trials.

The Europe, Middle East & Africa region presents a mosaic of regulatory models and reimbursement systems. While some European jurisdictions offer collaborative assessment frameworks and health technology assessment pathways that reward long-term value, others require extensive local evidence generation. The region's manufacturing landscape is evolving with investments in capacity and specialized service providers, yet companies navigating this geography must reconcile cross-border regulatory variances and diverse healthcare funding mechanisms. Capacity-building initiatives and public-private partnerships are increasingly important levers to expand access in parts of the region where infrastructure remains nascent.

Asia-Pacific combines rapidly maturing clinical trial capabilities with ambitious national strategies to become hubs for biotechnology manufacturing and commercialization. Governments across the region are investing in biotechnology infrastructure, streamlined regulatory pathways for advanced therapies, and talent development programs. This creates both opportunity and complexity: sponsors can access large patient populations and lower development costs, but must also adapt to different regulatory expectations, local manufacturing requirements, and market access criteria.

Attuning strategy to these regional differences is essential for aligning trial design, manufacturing placement, and commercial access plans with local regulatory realities and payer expectations.

How company strategies focused on integration, platform specialization, and service excellence are reshaping competitive positioning across the cell and gene therapy value chain

Company-level strategies are converging around a set of core capabilities that differentiate winners from also-rans in the advanced therapy arena. Leading organizations are investing in vertically integrated capabilities that span discovery, vector and cell engineering, process development, and commercial-scale manufacturing, while also maintaining flexible partnerships that allow rapid capacity expansion. Others are specializing in platform technologies-such as modular manufacturing systems, high-titer vector production, or closed-system cell processing-that they can license or operate as contract services, thereby capturing value through scale and reproducibility.

Service providers and contract manufacturers are playing an increasingly strategic role by offering end-to-end solutions that reduce time-to-clinic for sponsors and lower technical risk. Companies that excel in quality systems, regulatory compliance, and supply chain orchestration are securing long-term relationships with sponsors by guaranteeing throughput and minimizing release delays. Meanwhile, developers are differentiating through clinical program design, biomarker-driven patient selection, and payer engagement strategies that translate clinical benefit into credible health economic narratives.

Investor and corporate development activity is focused on capabilities that address the industry's most pressing bottlenecks: scalable vector production, automation of cell handling, robust analytics for potency and comparability, and digitized batch record systems. Across these company archetypes, success correlates with the ability to demonstrate reproducible manufacturing, credible clinical outcomes, and a commercialization plan that accounts for reimbursement complexity and international market entry barriers.

Actionable strategic priorities for leaders to strengthen supply resilience, scale manufacturing, align regulatory strategy, and accelerate payer adoption

Industry leaders should prioritize a set of pragmatic actions to translate scientific advantage into durable commercial success. First, strengthening supplier partnerships and dual sourcing for critical inputs will mitigate exposure to geopolitical and tariff-driven disruptions while enabling continuity of clinical supply. Simultaneously, investing in modular manufacturing capabilities and automation can reduce batch variability and improve unit economics, creating optionality for both in-house production and contract manufacturing partnerships. In parallel, establishing clear regulatory engagement plans that incorporate real-world evidence strategies and post-approval data collection will accelerate payer conversations and support outcome-based contracting models.

Operationally, organizations should accelerate digitalization of quality systems and batch analytics to enable more predictive manufacturing control and faster regulatory submissions. Cross-functional alignment between R&D, manufacturing, and commercial teams is essential: integrated project governance that links clinical milestones to manufacturing readiness and market access requirements will reduce delays during transition to late-stage development. Collaboration with healthcare providers to design feasible administration pathways-particularly for complex cell therapies requiring specialized infusion centers-will ensure patient access and streamline adoption.

Finally, scenario-based strategic planning that models tariff outcomes, regulatory shifts, and capacity constraints will help leadership teams prioritize investments and partnership choices. By combining supply chain resilience, manufacturing scalability, regulatory foresight, and payer-focused evidence generation, industry leaders can de-risk development pathways and create sustainable routes to patient access.

A rigorous mixed-methods research approach that combines primary stakeholder interviews, regulatory and patent analysis, and process mapping to validate operational and strategic insights

This analysis synthesizes multiple evidence streams to construct a robust and reproducible view of current dynamics in the cell and gene therapy sector. Primary research included structured interviews with stakeholders across discovery organizations, clinical development teams, manufacturing and supply chain leaders, regulatory affairs experts, and payers. Secondary research drew on peer-reviewed literature, publicly available regulatory guidance, clinical trial registries, company disclosures, patent filings, and logistics and cold-chain studies to triangulate operational and scientific trends.

Analytical methods included process mapping of manufacturing workflows to identify common bottlenecks, comparative regulatory analysis to surface jurisdictional variances, and qualitative coding of expert interviews to highlight recurring strategic themes. Scenario analysis was employed to evaluate the operational implications of tariff changes and supply chain disruptions. Where appropriate, findings were validated through cross-checks with subject matter experts to reduce bias and ensure technical accuracy. Limitations include the pace of innovation in the field, which can create rapid shifts in capability and regulation, and the variability of proprietary manufacturing processes that limit direct comparability across all developers.

Despite these constraints, the methodology emphasizes triangulation and expert validation to produce insights that are actionable for strategic decision-making, investment evaluation, and operational planning.

Concluding synthesis that links scientific progress to operational readiness and commercial pathways for achieving durable patient access and business sustainability

The cell and gene therapy field is entering a phase where strategic execution, not just scientific novelty, will determine which therapies achieve lasting clinical and commercial impact. Scientific advances continue to expand the range of treatable conditions and improve the precision of interventions, yet the path to patients demands concerted attention to manufacturing scale-up, supply chain robustness, regulatory alignment, and payer evidence generation. Leaders who proactively build resilient supplier networks, adopt modular manufacturing and digital quality systems, and engage payers with credible real-world evidence narratives will be best positioned to translate clinical success into broad patient access.

The interplay of regional regulatory approaches, tariff dynamics, and commercial models means that global strategies must be flexible and locally adapted. Organizations that blend platform investments with smart partnerships and that apply scenario planning to geopolitical and policy changes will reduce execution risk. Above all, integrating scientific, operational, and commercial planning across the organization will accelerate transitions from demonstration to widespread adoption, ensuring therapies reach the patients who need them while maintaining sustainable business models.

Taken together, these priorities offer a practical roadmap for converting innovation into impact in a competitive and rapidly evolving environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of allogeneic CAR T-cell therapies targeting solid tumors through universal donor platforms
  • 5.2. Integration of CRISPR-based gene editing in in vivo therapies for rare genetic disorders to improve safety and efficacy
  • 5.3. Adoption of automated closed-system manufacturing to reduce costs and scale production of personalized cell therapies
  • 5.4. Development of next-generation AAV vector platforms to enhance tissue specificity and decrease immunogenicity in gene therapies
  • 5.5. Implementation of decentralized point-of-care manufacturing models for on-site production of autologous cell therapies
  • 5.6. Emergence of multi-specific and armored CAR T-cell constructs to overcome tumor microenvironment immunosuppression
  • 5.7. Strategic partnerships between biotech firms and CDMOs to accelerate clinical development and commercialization of cell therapies
  • 5.8. Regulatory harmonization efforts to streamline global approval pathways and accelerate patient access to gene treatments
  • 5.9. Application of artificial intelligence and digital twins for process analytics and optimization in cell therapy manufacturing
  • 5.10. Investment in supply chain innovations, including cryopreservation and cold chain logistics, to ensure cell product viability worldwide

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cell & Gene Therapy Market, by Therapy Type

  • 8.1. Cell Therapy
    • 8.1.1. Stem Cell Therapies
      • 8.1.1.1. Hematopoietic Stem Cell Therapies
      • 8.1.1.2. Mesenchymal Stem Cell Therapies
    • 8.1.2. T Cell Therapy
      • 8.1.2.1. CAR T Cell Therapy
      • 8.1.2.2. T Cell Receptor (TCR)-based
  • 8.2. Gene Therapy
    • 8.2.1. Ex Vivo Gene Therapy
    • 8.2.2. In Vivo Gene Therapy

9. Cell & Gene Therapy Market, by Delivery Method

  • 9.1. Intramuscular
  • 9.2. Intravenous

10. Cell & Gene Therapy Market, by Therapeutic Areas

  • 10.1. Cardiovascular
    • 10.1.1. Congestive Heart Failure
    • 10.1.2. Ischemic Heart Disease
  • 10.2. Metabolic Disorders
    • 10.2.1. Diabetes
    • 10.2.2. Obesity
  • 10.3. Neurological Disorders
    • 10.3.1. Alzheimer's Disease
    • 10.3.2. Huntington's Disease
    • 10.3.3. Multiple Sclerosis
    • 10.3.4. Parkinson's Disease
    • 10.3.5. Spinal Cord Injuries
  • 10.4. Oncology
    • 10.4.1. Hematological Malignancies
    • 10.4.2. Lymphomas
    • 10.4.3. Solid Tumors
  • 10.5. Ophthalmology

11. Cell & Gene Therapy Market, by Application

  • 11.1. Clinical Applications
    • 11.1.1. Disease Prevention
    • 11.1.2. Disease Treatment
  • 11.2. Research & Development

12. Cell & Gene Therapy Market, by End User

  • 12.1. Academic & Research Institutes
    • 12.1.1. Private Research Labs
    • 12.1.2. Universities
  • 12.2. Hospitals & Clinics

13. Cell & Gene Therapy Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cell & Gene Therapy Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cell & Gene Therapy Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. AbbVie Inc.
    • 16.3.2. Abeona Therapeutics Inc.
    • 16.3.3. Adaptimmune Therapeutics PLC
    • 16.3.4. AGC Inc.
    • 16.3.5. Alnylam Pharmaceuticals, Inc.
    • 16.3.6. American Gene Technologies Inc.
    • 16.3.7. Amgen Inc.
    • 16.3.8. AnGes, Inc
    • 16.3.9. Astellas Pharma Inc.
    • 16.3.10. Becton, Dickinson and Company
    • 16.3.11. Biogen Inc.
    • 16.3.12. Bluebird Bio, Inc.
    • 16.3.13. BridgeBio Pharma, Inc.
    • 16.3.14. Bristol-Myers Squibb Company
    • 16.3.15. C.H. Boehringer Sohn AG & Co. KG
    • 16.3.16. Cellectis SA
    • 16.3.17. CRISPR Therapeutics AG
    • 16.3.18. F. Hoffmann-La Roche AG
    • 16.3.19. Gilead Sciences, Inc.
    • 16.3.20. Intellia Therapeutics, Inc.
    • 16.3.21. Ionis Pharmaceuticals, Inc.
    • 16.3.22. Johnson & Johnson Services Inc.
    • 16.3.23. Kyowa Kirin Co., Ltd.
    • 16.3.24. Merck KGaA
    • 16.3.25. Moderna, Inc.
    • 16.3.26. Mustang Bio, Inc.
    • 16.3.27. Novartis AG
    • 16.3.28. Novo Nordisk A/S
    • 16.3.29. Pfizer, Inc.
    • 16.3.30. REGENXBIO Inc.
    • 16.3.31. Sangamo Therapeutics, Inc.
    • 16.3.32. Sarepta Therapeutics, Inc.
    • 16.3.33. Shoreline Biosciences
    • 16.3.34. Sibiono GeneTech Co. Ltd.
    • 16.3.35. Syncona Limited
    • 16.3.36. Thermo Fisher Scientific Inc.
    • 16.3.37. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELL & GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. CELL & GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. CELL & GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CELL & GENE THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CELL & GENE THERAPY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CELL & GENE THERAPY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CAR T CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CAR T CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CAR T CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CAR T CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CAR T CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CAR T CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL RECEPTOR (TCR)-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL RECEPTOR (TCR)-BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL RECEPTOR (TCR)-BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL RECEPTOR (TCR)-BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL RECEPTOR (TCR)-BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL RECEPTOR (TCR)-BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY EX VIVO GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY EX VIVO GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY EX VIVO GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY EX VIVO GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY EX VIVO GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY EX VIVO GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY IN VIVO GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY IN VIVO GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY IN VIVO GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY IN VIVO GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY IN VIVO GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY IN VIVO GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ISCHEMIC HEART DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ISCHEMIC HEART DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ISCHEMIC HEART DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ISCHEMIC HEART DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ISCHEMIC HEART DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ISCHEMIC HEART DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DIABETES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DIABETES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DIABETES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DIABETES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DIABETES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DIABETES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY OBESITY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY OBESITY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY OBESITY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY OBESITY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY OBESITY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY OBESITY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HUNTINGTON'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HUNTINGTON'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HUNTINGTON'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HUNTINGTON'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HUNTINGTON'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HUNTINGTON'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY SPINAL CORD INJURIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY SPINAL CORD INJURIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY SPINAL CORD INJURIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY SPINAL CORD INJURIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY SPINAL CORD INJURIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY SPINAL CORD INJURIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY LYMPHOMAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY LYMPHOMAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY LYMPHOMAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY LYMPHOMAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY LYMPHOMAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY LYMPHOMAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY OPHTHALMOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY OPHTHALMOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY OPHTHALMOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY OPHTHALMOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DISEASE PREVENTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DISEASE PREVENTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DISEASE PREVENTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DISEASE PREVENTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DISEASE PREVENTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DISEASE PREVENTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DISEASE TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DISEASE TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DISEASE TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DISEASE TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DISEASE TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DISEASE TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PRIVATE RESEARCH LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PRIVATE RESEARCH LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PRIVATE RESEARCH LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PRIVATE RESEARCH LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PRIVATE RESEARCH LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PRIVATE RESEARCH LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY UNIVERSITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY UNIVERSITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 300. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 306. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
  • TABLE 308. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2025-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 310. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 311. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 312. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2032 (USD M